Aquestive Therapeutics, Inc. Accounts Receivable, Allowance for Credit Loss, Recovery
Aquestive Therapeutics, Inc. (AQST) reported Accounts Receivable, Allowance for Credit Loss, Recovery of $0 for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-05.
Discontinued › Notes › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries · last filed 2020-05-05
- Aquestive Therapeutics, Inc. accounts receivable, allowance for credit loss, recovery for the quarter ending 2020-03-31 was $0.00.
- Aquestive Therapeutics, Inc. accounts receivable, allowance for credit loss, recovery for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- Aquestive Therapeutics, Inc. accounts receivable, allowance for credit loss, recovery for the quarter ending 2018-09-30 was $0.00.
- Aquestive Therapeutics, Inc. accounts receivable, allowance for credit loss, recovery for the quarter ending 2017-12-31 was $15.00K.
- Aquestive Therapeutics, Inc. accounts receivable, allowance for credit loss, recovery for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Aquestive Therapeutics, Inc. accounts receivable, allowance for credit loss, recovery for fiscal 2017 was $53.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Recovery 3 month | Accounts Receivable, Allowance for Credit Loss, Recovery 6 month | Accounts Receivable, Allowance for Credit Loss, Recovery 9 month | Accounts Receivable, Allowance for Credit Loss, Recovery 12 month |
|---|---|---|---|---|
| 2020-03-31 | $0.00 10-Q · filed 2020-05-05 | |||
| 2019-12-31 | $0.00 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $0.00 derived: sum of 2 quarters · filed 2020-03-11 | $0.00 10-K · filed 2020-03-11 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-09-04 | |||
| 2017-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $53.00K 10-K · filed 2019-03-14 | ||
| 2017-09-30 | $38.00K 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |